(Information sent by the signatory company)
MADRID, May 9, 2024 /PRNewswire/ — mAbxience, a leading company in the development and manufacturing of biopharmaceutical products, and part of the Fresenius Kabi and Insud Pharma groups, today announced the appointment of Jurgen Van Broeck as CEO (Chief Executive Officer). Jurgen, who has served as Global Commercial Director since June 2023, brings extensive experience and a proven track record in the pharmaceutical and biosimilar industries.
Prior to his new role, Jurgen has been leading mAbxience’s strategic initiatives, overseeing all commercial, business development and market access activities. He has been instrumental in directing the company’s strategic alliances and establishing the growth trajectory of our CDMO (Contract Development and Manufacturing Organization) services. Under his leadership, mAbxience has successfully strengthened its global presence and continued to excel in providing high-quality, affordable medicines around the world.
Jurgen joined mAbxience with almost two decades of extensive experience in the healthcare sector, including senior positions at multinational companies such as Merck and Mundipharma. His experience has been particularly instrumental in launching the first immunological biosimilar in multiple regions, securing significant internal and external licensing agreements, and leading commercial operations in multiple regions.
Jurgen commented on his new role: “I am honored to lead mAbxience in this exciting phase of the company’s growth, as we continue to strive for excellence in everything we do. Our mission to provide quality, affordable biologic medicines and providing world-class CDMO services remains at the core of our strategy. I look forward to working closely with our excellent team to advance our pipeline, expand our global presence and become a well-known biologics CDMO. Worldwide”.
mAbxience remains committed to its mission of improving quality of life through universal access to high-quality biopharmaceuticals. With a strong product portfolio and strategic alliances in more than 100 markets, mAbxience is poised to maintain its track record as a leading global biopharmaceutical company under Jurgen’s leadership.
About mAbxience: mAbxience is a company based in Spain specialized in the development, production and marketing of biopharmaceutical products. In August 2022, Fresenius Kabi and Insud Pharma signed an agreement whereby Fresenius Kabi acquired a majority stake in mAbxience, establishing it as a global, vertically integrated biotechnology company. Fresenius Kabi is a company of the global healthcare group Fresenius.
For more information about mAbxience, its biosimilars or CDMO’s business area, visit the website www.mabxience.com or contact via LinkedIn.
Photo: https://mma.prnewswire.com/media/2408752…
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/mabxience-nombra-a-jurgen-van-broeck-nuevo-ceo-302141070.html